Sugi Predict

Sugi Predict / Compounds / SCHEMBL2862629

SCHEMBL2862629

SCHEMBL2862629

O=Cc1ccc(C(F)(F)C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 4/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ ALDH5A1 P51649 1/20 0.42
▸ ABAT P80404 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ TYR P14679 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP2A13 Q16696 1/20 0.38
▸ CYP1A2 P05177 1/20 0.36
▸ ALDH1A3 P47895 2/20 0.35
▸ ALDH3A1 P30838 1/20 0.35
▸ DRD1 P21728 1/20 0.35
▸ ESR1 P03372 1/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13989020 0.94 KIF11 (0.49) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL19056951 0.86 CYP2A6 (0.42) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL16626288 0.84 CYP1A2 (0.48) CYP2A6HSD17B10ALDH5A1ABATKIF11
SCHEMBL19056941 0.84 CYP2A6 (0.41) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL5723649 0.83 ESR1 (0.52) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL13410410 0.83 CYP2A6 (0.37) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL16626101 0.82 ALDH1A1 (0.54) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL3244125 0.81 CYP2A6 (0.42) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL11358406 0.81 CYP2A6 (0.42) CYP2A6HSD17B10ALDH5A1ABATALDH1A1
SCHEMBL61631 0.80 CYP1A2 (0.54) CYP2A6HSD17B10ALDH5A1ABATALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 — — US disclosed
CN-117673469-A Electrolyte for secondary battery and secondary battery 蓝固(湖州)新能源科技有限公司 2024-03-08 — — CN disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-11458149-B1 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-10-04 — — US disclosed
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-01-24 — — US disclosed
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-01-24 — — US disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 — — US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 — — WO disclosed
EP-1805141-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LTD. (GB) 2007-07-11 — — EP disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
WO-2006043064-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-04-27 — — WO disclosed
WO-2006043064-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-04-27 — — WO disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 CYP2A6 30/4885HSD17B10 1465/4885ALDH5A1 707/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP2A6 1119/4885HSD17B10 467/4885ALDH5A1 621/4885
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease PSEN1, PSEN2, APP CYP2A6 2812/4885HSD17B10 3049/4885ALDH5A1 1421/4885
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CYP2A6 2559/4885HSD17B10 622/4885ALDH5A1 612/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CYP2A6 2559/4885HSD17B10 622/4885ALDH5A1 612/4885
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC CYP2A6 89/4885HSD17B10 2275/4885ALDH5A1 1117/4885
US-11458149-B1 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CYP2A6 2559/4885HSD17B10 622/4885ALDH5A1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.